Cansino Biologics vs Zhejiang Huahai Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Cansino Biologics Inc (688185.CG)

Q3 202619 Jul – 4 Oct 2026

▲4

CanSino's pipeline expands, but mRNA cancer vaccine hopes stay early-stage

Meningococcal vaccine age expansion filed China's drug regulator accepted CanSino's application to widen the age range of its four-strain meningitis vaccine Manhaixin to 3 months–17 years. Approval would let it sell to more children and teens, supporting future revenue, though the company says it won't change current results.
A concrete regulatory step that can expand the market for an already-sold product.
DTP vaccine launches and adult version filed CanSino's infant DTP combination vaccine Pancocin began shipping after batch release, and a version for people aged six and older had its registration application accepted. These add real product sales and fill a gap in China's adult booster market, though profits will build over time.
Two pipeline milestones that turn into actual product supply and a new market segment.
mRNA cancer vaccine deal sparks huge rally After Moderna and Merck's cancer vaccine succeeded in a late-stage trial, CanSino signed a deal with Dephios Bio to co-develop a personalized mRNA cancer vaccine. The stock hit its 20% daily limit repeatedly, but the product is years from market and the company itself calls it early-stage.
The main force behind the period's sharp price moves, with an important early-stage caveat.
Government pharma plan lifts sector China's industry ministry and nine departments released a five-year plan targeting over 3.5 trillion yuan in drug industry revenue and faster innovative-drug growth. The policy boosted the whole biotech sector, and CanSino hit its 20% limit again, though this is sector-wide sentiment rather than company-specific news.
A policy catalyst that lifted CanSino along with peers, but not driven by its own results.

August 202619 Jul – 4 Oct 2026

▲4

CanSino's pipeline expands, but mRNA cancer vaccine hopes stay early-stage

Meningococcal vaccine age expansion filed China's drug regulator accepted CanSino's application to widen the age range of its four-strain meningitis vaccine Manhaixin to 3 months–17 years. Approval would let it sell to more children and teens, supporting future revenue, though the company says it won't change current results.
A concrete regulatory step that can expand the market for an already-sold product.
DTP vaccine launches and adult version filed CanSino's infant DTP combination vaccine Pancocin began shipping after batch release, and a version for people aged six and older had its registration application accepted. These add real product sales and fill a gap in China's adult booster market, though profits will build over time.
Two pipeline milestones that turn into actual product supply and a new market segment.
mRNA cancer vaccine deal sparks huge rally After Moderna and Merck's cancer vaccine succeeded in a late-stage trial, CanSino signed a deal with Dephios Bio to co-develop a personalized mRNA cancer vaccine. The stock hit its 20% daily limit repeatedly, but the product is years from market and the company itself calls it early-stage.
The main force behind the period's sharp price moves, with an important early-stage caveat.
Government pharma plan lifts sector China's industry ministry and nine departments released a five-year plan targeting over 3.5 trillion yuan in drug industry revenue and faster innovative-drug growth. The policy boosted the whole biotech sector, and CanSino hit its 20% limit again, though this is sector-wide sentiment rather than company-specific news.
A policy catalyst that lifted CanSino along with peers, but not driven by its own results.

Latest19 Jul – 4 Oct 2026

▲4

CanSino's pipeline expands, but mRNA cancer vaccine hopes stay early-stage

Meningococcal vaccine age expansion filed China's drug regulator accepted CanSino's application to widen the age range of its four-strain meningitis vaccine Manhaixin to 3 months–17 years. Approval would let it sell to more children and teens, supporting future revenue, though the company says it won't change current results.
A concrete regulatory step that can expand the market for an already-sold product.
DTP vaccine launches and adult version filed CanSino's infant DTP combination vaccine Pancocin began shipping after batch release, and a version for people aged six and older had its registration application accepted. These add real product sales and fill a gap in China's adult booster market, though profits will build over time.
Two pipeline milestones that turn into actual product supply and a new market segment.
mRNA cancer vaccine deal sparks huge rally After Moderna and Merck's cancer vaccine succeeded in a late-stage trial, CanSino signed a deal with Dephios Bio to co-develop a personalized mRNA cancer vaccine. The stock hit its 20% daily limit repeatedly, but the product is years from market and the company itself calls it early-stage.
The main force behind the period's sharp price moves, with an important early-stage caveat.
Government pharma plan lifts sector China's industry ministry and nine departments released a five-year plan targeting over 3.5 trillion yuan in drug industry revenue and faster innovative-drug growth. The policy boosted the whole biotech sector, and CanSino hit its 20% limit again, though this is sector-wide sentiment rather than company-specific news.
A policy catalyst that lifted CanSino along with peers, but not driven by its own results.

Zhejiang Huahai Pharmaceutical Co Ltd (600521.CG)

Q3 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

August 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

Latest24 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.